By Counterforce Health Team in Givlaari (givosiran) —

Renewing Givlaari (Givosiran) Approval with UnitedHealthcare in California: Complete 2025 Guide

Answer Box: To renew Givlaari (givosiran) with UnitedHealthcare in California, submit annual prior authorization 30-45 days before expiration with: (1) Recent ALA/PBG lab values, (2) documented attack reduction from baseline, (3) specialist attestation of ongoing medical necessity, and (4) liver function monitoring results. Use the UnitedHealthcare provider portal for submission. If denied, California residents can appeal through internal review (15 days) then Independent Medical Review (IMR) through DMHC with a 68% success rate for specialty drugs.

Table of Contents

  1. Renewal Triggers: When to Start
  2. Evidence Update: What You Need to Prove
  3. Renewal Packet: Must-Include Documents
  4. Timeline: Submission Windows & Decisions
  5. If Coverage Lapses: Bridge Options
  6. Annual Changes: What to Re-verify
  7. Appeals Process for California
  8. Personal Tracker Template
  9. FAQ

Renewal Triggers: When to Start

UnitedHealthcare typically approves Givlaari for 6-12 month periods, requiring annual renewal for continued coverage. Start your renewal process 30-45 days before your current authorization expires to avoid treatment interruptions.

Early Warning Signs to Begin Renewal:

  • Authorization expiration notice from UnitedHealthcare or OptumRx
  • Pharmacy notification of upcoming coverage end date
  • Provider portal alerts about pending renewals
  • Attack frequency changes that may require documentation updates
Tip: Mark your calendar 60 days before expiration to gather documentation early, as lab results and specialist appointments may take weeks to obtain.

Evidence Update: What You Need to Prove

Your renewal must demonstrate continued medical necessity and positive treatment response. UnitedHealthcare requires specific evidence categories:

Clinical Response Documentation

  • Attack frequency reduction: Compare current attack rate to pre-treatment baseline
  • ALA/PBG levels: Recent (within 12 months) urinary aminolevulinic acid and porphobilinogen results showing sustained reduction
  • Hemin usage: Documentation of reduced rescue hemin requirements
  • Quality of life improvements: Symptom reduction, hospitalization avoidance

Safety Monitoring Results

According to UnitedHealthcare's Givlaari policy, ongoing monitoring must include:

  • Monthly liver function tests (ALT/AST) for first 6 months, then as clinically indicated
  • Renal function monitoring as recommended
  • Documentation of dose adjustments if transaminase elevations occurred

Adherence Documentation

  • Pharmacy claims review showing ≥85% adherence to monthly dosing schedule
  • Provider administration records confirming consistent subcutaneous injections
  • No concomitant prophylactic hemin use (rescue hemin is acceptable)

Renewal Packet: Must-Include Documents

Core Requirements Checklist

  • Specialist attestation from hematologist, hepatologist, or gastroenterologist
  • ICD-10 diagnosis code E80.21 (acute intermittent porphyria) or appropriate AHP subtype
  • Lab results: Recent ALA/PBG levels with reference ranges and trend from baseline
  • Attack log: Detailed record showing frequency reduction compared to pre-treatment
  • Safety monitoring: LFT results and any dose modifications
  • Prior therapy documentation: Evidence of hemin trial/failure or contraindication
  • Current dosing: 2.5 mg/kg monthly (or adjusted dose if applicable)

Letter of Medical Necessity Structure

Your specialist should include:

  1. Confirmed AHP diagnosis with genetic or biochemical confirmation
  2. Treatment history: Pre-Givlaari attack frequency and hemin usage
  3. Current response: Specific metrics showing improvement
  4. Ongoing need: Why continued therapy is medically necessary
  5. Safety profile: Monitoring results and tolerance

Timeline: Submission Windows & Decisions

Phase Timeline Action Required
Pre-submission 45-60 days before expiration Gather documentation, schedule specialist visit
Submission 30-45 days before expiration Submit complete renewal packet via provider portal
Initial review 15 business days UnitedHealthcare processes request
Decision Up to 30 days total Approval, denial, or request for additional information
Appeal (if needed) Within 180 days of denial Internal appeal process begins
Note: California regulations require health plans to provide adequate time for appeals before coverage expires, but starting early prevents gaps.

If Coverage Lapses: Bridge Options

If your Givlaari renewal is delayed or denied, immediate action is needed to prevent AHP attacks:

Bridge Therapy Options

  • IV hemin prophylaxis: Most payers cover Panhematin during documented coverage gaps
  • Attack management protocol: Ensure emergency hemin access for breakthrough attacks
  • Trigger avoidance: Strict adherence to dietary and medication restrictions

Emergency Coverage Requests

  • Expedited appeals: Available for urgent medical situations
  • Emergency supply: Some plans provide temporary medication while appeals are processed
  • Provider samples: Contact Alnylam through Alnylam Assist for potential bridge support

Annual Changes: What to Re-verify

UnitedHealthcare updates coverage policies annually. For 2025, key changes include:

New Requirements to Verify

  • Prior authorization criteria: Check current UnitedHealthcare policy documents for updates
  • Formulary tier changes: Verify Givlaari's current tier status affects your copay
  • Provider network: Confirm your specialist remains in-network
  • OptumRx requirements: Specialty pharmacy protocols may change
Important: The 2025 Medicare Part D reforms introduced a $2,000 annual out-of-pocket maximum, potentially reducing your costs significantly if you have Medicare coverage.

Appeals Process for California

California residents have robust appeal rights through the Department of Managed Health Care (DMHC):

Internal Appeal Process

  1. File with UnitedHealthcare within 180 days of denial
  2. Standard review: 15 days for decision
  3. Expedited review: 72 hours for urgent situations
  4. Required documentation: Medical records, specialist letters, clinical evidence

Independent Medical Review (IMR)

If internal appeal fails:

  • File with DMHC within 6 months of final internal denial
  • Timeline: 30 days for standard review, 3-7 days for expedited
  • Success rate: 68% of specialty drug IMRs are approved
  • Binding decision: UnitedHealthcare must comply within 5 days if approved

Contact the DMHC Help Center at 888-466-2219 for assistance with the IMR process.

Personal Tracker Template

Use this template to organize your renewal:

Key Dates

  • Current authorization expires: ___________
  • Renewal submission target: ___________
  • Specialist appointment scheduled: ___________
  • Lab work completed: ___________

Documentation Status

  • Recent ALA/PBG results obtained
  • Attack log updated through current date
  • LFT results within last 3 months
  • Specialist letter requesting continuation
  • Prior authorization form completed
  • All documents submitted via provider portal

Follow-up Actions

  • Decision received date: ___________
  • If denied, internal appeal filed by: ___________
  • IMR requested (if needed) by: ___________

FAQ

How long does UnitedHealthcare prior authorization take for Givlaari renewal? Standard renewals take up to 30 days, but most decisions are made within 15 business days when complete documentation is provided.

What if my attack frequency hasn't decreased significantly? Document other benefits like reduced severity, shorter duration, decreased hemin requirements, or improved quality of life metrics. Stable disease can justify continuation.

Can I request expedited renewal if my authorization is expiring soon? Yes, if there's urgent medical need. Your doctor must document that delay could seriously jeopardize your health.

What happens if UnitedHealthcare changes their Givlaari policy mid-year? Existing authorizations typically continue until expiration, but new requirements may apply to renewals. Monitor policy updates through the provider portal.

Does step therapy apply to Givlaari renewals? Usually no, since you've already demonstrated hemin failure or intolerance. However, verify current policy requirements as criteria can change.

How do I access my prescription history for the renewal application? Log into your UnitedHealthcare member portal or request pharmacy claims history from OptumRx to document adherence.

Counterforce Health specializes in turning insurance denials into successful appeals by analyzing denial letters, payer policies, and clinical documentation to create targeted, evidence-backed responses. Our platform helps patients and providers navigate complex prior authorization requirements and appeal processes for specialty medications like Givlaari.

For additional support with your Givlaari renewal or appeal, visit Counterforce Health to learn how our platform can strengthen your case with payer-specific documentation and clinical evidence.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance plan for specific coverage decisions. Coverage policies vary by plan type and may change. For official appeals assistance in California, contact the DMHC at 888-466-2219.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.